DNA · Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks has executed a significant strategic shift by divesting its entire Biosecurity segment through a transaction completed on April 3, 2026. The company exchanged all equity interests in its Biosecurity subsidiary for a minority stake representing approximately 20% of Tower Biosecurity, Inc. (also known as Perimeter Systems, Inc.). This disposition qualifies as discontinued operations under accounting standards, meaning historical Biosecurity financial results will be separated from continuing operations in all future financial reporting, beginning with the first quarter of 2026. The pro forma financial statements illustrate the operational impact of removing the Biosecurity segment, which generated $37.4 million, $53.1 million, and $107.9 million in revenue during 2025, 2024, and 2023 respectively. The transaction adjustments include recording a $12.3 million equity investment in the purchaser and minor liability transfers, while the company entered into a Transition Services Agreement for temporary support services. This strategic move allows Ginkgo to focus exclusively on its core Cell Engineering business, though it results in the loss of a revenue stream that previously contributed to overall top-line results.